Arrowhead製藥 ARWR 深 滬
已收盤 08-29 16:00:00 美东时间
22.03
-0.310
-1.39%
華盛通- 最 高22.55
- 今 開22.43
- 成交量 238.87万股
- 最 低 21.61
- 昨 收 22.34
- 總市值 30.40亿
- 52周最高 27.34
- 市盈率 靜 --
- 換手率 1.73%
- 52周最低 9.57
- 委 比 20.53%
- 總股本 1.38亿
- 歷史最高 93.66
- 量 比 1.06
- 振 幅 4.21%
- 歷史最低 1.22
- 每 手 1
- 風險率 4.32%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Arrowhead Pharmaceuticals Redeems ~$50M Of Arrowhead Stock; Receives ~$50M In Cash In Satisfaction Of Milestone from Sarepta Therapeutics
- Arrowhead has elected to receive approximately $50 million worth of Arrowhead common stock from Sarepta, which will be placed into treasury and reduce the number of Arrowhead shares outstanding - The remainder of the recently earned $100 million milestone, or approximately $50 million, will be received in cash
08-14 04:27
Arrowhead Pharmaceuticals’ Earnings Call Highlights Strategic Progress
Arrowhead Pharmaceuticals, Inc. (($ARWR)) has held its Q3 earnings call. Read o...
08-12 08:57
美股大行评级 | 潜在涨幅286.44%！RBC Capital上调Edgewise Therapeutics目标价至49美元，维持"跑赢大市"评级
今日重点评级关注：RBC Capital：维持Edgewise Therapeutics"跑赢大市"评级，目标价从48美元升至49美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从6美元升至7美元
08-11 09:43
RBC Capital Maintains Outperform on Arrowhead Pharma, Lowers Price Target to $38
RBC Capital analyst Luca Issi maintains Arrowhead Pharma (NASDAQ:ARWR) with a Outperform and lowers the price target from $40 to $38.
08-09 01:20
Arrowhead Pharma Q3 EPS $(1.26) Misses $(0.89) Estimate, Sales $27.767M Beat $23.711M Estimate
Arrowhead Pharma (NASDAQ:ARWR) reported quarterly losses of $(1.26) per share which missed the analyst consensus estimate of $(0.89) by 41.57 percent. This is a 8.7 percent increase over losses of $(1.38) per share from
08-08 04:04
Here are the major earnings after the close Thursday
Major earnings expected after the bell on Thursday include: Block (XYZ) Gilead Sciences (GILD) Twilio (TWLO) The Trade Desk (TTD) Main Street Capital Corporation (MAIN) Other earnings slated for rele...
08-07 22:00
Earnings Scheduled For August 7, 2025
Companies Reporting Before The Bell • GoHealth (NASDAQ:GOCO) is estimated to re...
08-07 16:33
Sarepta Therapeutics Surges Over 40% In Tuesday Pre-Market: What's Going On?
Stock of Sarepta Therapeutics Inc. (NASDAQ: SRPT) surged 38.89% in Tuesday pre-market following the U.S. Food and Drug Administration's (FDA) recommendation to lift the voluntary hold on Elevidys, Sarepta's gene therapy for Duchenne Muscular Dystrophy.
07-29 17:41
FDA Probes Death Of 8-Year-Old Who Received Sarepta's Elevidys
FDA probes Elevidys after an 8-year-old's death in Brazil; Sarepta and Roche say the death was unrelated to gene therapy treatment.
07-28 20:48
Arrowhead Pharmaceuticals earns $100M milestone from Sarepta Therapeutics
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Monday announced that it has earned a $100 million milestone payment from Sarepta Therapeutics (NASDAQ:SRPT). The milestone was triggered when Arrowhead reached...
07-28 20:27
